Impact of Lactoferrin Supplementation on Growth and Prevalence of<i>Giardia</i>Colonization in Children

Ochoa, Theresa J.; Chea-Woo, Elsa; Campos, Miguel; Pecho, Iris; Prada, Ana; McMahon, Robert J.; Cleary, Thomas G.

doi:10.1086/588476

Cited by 78 publications

(52 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Tests carried out on mandarins with bLfcin and Lf (17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31) showed a significant protection against Penicillium digitatum at a concentration close to the in vitro MIC value [115]. More recently Baruzzi et al demonstrated the interesting activity of bLfcin in controlling microbial spoilage in ready-to-eat leafy vegetables during cold storage [116].…”

Section: Fruits and Vegetablesmentioning

confidence: 99%

Antimicrobial Activity of Lactoferrin-Related Peptides and Applications in Human and Veterinary Medicine

Bruni¹,

et al. 2016

View full text Add to dashboard Cite

Antimicrobial peptides (AMPs) represent a vast array of molecules produced by virtually all living organisms as natural barriers against infection. Among AMP sources, an interesting class regards the food-derived bioactive agents. The whey protein lactoferrin (Lf) is an iron-binding glycoprotein that plays a significant role in the innate immune system, and is considered as an important host defense molecule. In search for novel antimicrobial agents, Lf offers a new source with potential pharmaceutical applications. The Lf-derived peptides Lf(1-11), lactoferricin (Lfcin) and lactoferrampin exhibit interesting and more potent antimicrobial actions than intact protein.Particularly, Lfcin has demonstrated strong antibacterial, anti-fungal and antiparasitic activity with promising applications both in human and veterinary diseases (from ocular infections to osteo-articular, gastrointestinal and dermatological diseases).

show abstract

Section: Fruits and Vegetablesmentioning

confidence: 99%

Antimicrobial Activity of Lactoferrin-Related Peptides and Applications in Human and Veterinary Medicine

Bruni¹,

et al. 2016

View full text Add to dashboard Cite

show abstract

“…We recently conducted a small community-based randomized double blind placebo controlled trial comparing twice daily oral supplementation with bovine lactoferrin (10−20% iron saturated, 1 g/day) (Tatua Cooperative Dairy Co, Morrinsville, New Zealand) versus placebo for 9 months in 52 Peruvian children 12−36 months of age [54]. Despite the small number of children enrolled in this study, several potentially useful observations were made related to bovine lactoferrin supplementation.…”

Section: Clinical Studies Of Lactoferrin's Effect On Enteric Pathogensmentioning

confidence: 99%

Effect of lactoferrin on enteric pathogens

Ochoa

Cleary²

2009

Biochimie

120

View full text Add to dashboard Cite

Much has been learned in recent years about the mechanisms by which breastfeeding improves child health and survival. However, there has been little progress in using these insights to improve pediatric care. Factors that are important for protecting the breast fed infant might be expected to decrease the adverse effects of weaning on diarrhea, growth, and development. Lactoferrin, an ironbinding protein with multiple physiological functions (anti-microbial, anti-inflammatory, and immunomodulatory), is one of the most important proteins present in mammalian milk. Protection against gastroenteritis is the most likely biologically relevant activity of lactoferrin. Multiple in vitro and animal studies have shown a protective effect of lactoferrin on infections with enteric microorganisms, including rotavirus, Giardia, Shigella, Salmonella and the diarrheagenic Escherichia coli. Lactoferrin has two major effects on enteric pathogens: it inhibits growth and it impairs function of surface expressed virulence factors thereby decreasing their ability to adhere or to invade mammalian cells. Thus, lactoferrin may protect infants from gastrointestinal infection by preventing the attachment by enteropathogens in the gut. Recently several clinical trials in children have started to address this issue. Whether lactoferrin can prevent a significant portion of diarrheal disease remains to be determined.

show abstract

“…Safety relevant endpoints were not studied. In two studies in Peruvian children which reported on adverse events the number of adverse events did not differ between the treatment and the placebo group and no adverse event could be attributed to the test substance (Ochoa et al, 2008;Zavaleta et al, 2007).…”

Section: Studies In Childrenmentioning

confidence: 93%

“…Four published studies with a duration of fifteen days to nine months investigated presumed antimicrobial effects of bLF at intakes between 100 and 1,000 mg per day alone or in coadministration with other substances (Ajello et al, 2002;Egashira et al, 2007;Ochoa et al, 2008;Zavaleta et al, 2007). Safety relevant endpoints were not studied.…”

Section: Studies In Childrenmentioning

confidence: 99%

Scientific Opinion on bovine lactoferrin

Products¹

2012

EFSA Journal

View full text Add to dashboard Cite

Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to carry out the additional assessment of "lactoferrin" as a food ingredient in the context of Regulation (EC) No 258/97 taking into account the comments and objections of a scientific nature raised by Member States. Bovine lactoferrin (bLF) is a protein that occurs naturally in cow"s milk. The applicant intends to market bLF as an ingredient for food supplements, infant and follow-on formulae, dietetic food for special medical purposes and sports nutrition, and for a variety of foods. For infants with an age of 0 -6 months, the applicant has estimated an intake of approximately 200 mg per kg bodyweight and 1.2 g bLF per day at the proposed use level. For adults, the mean and 95 th percentile daily intakes were calculated to be about 1.4 g and 3.4 g for an adult person. The toxicological information provided by the applicant included information from an in vitro genotoxicity study, a single dose study, a four week and a thirteen week oral repeated dose study in rats. The Panel notes that the estimated intake of "lactoferrin" for infants up to the age of one year of approximately 210 mg/kg bw per day would be around ten times lower than the highest dose (2,000 mg/kg bw per day) tested in the subchronic thirteen week rat study, which did not show adverse effects related to bLF. For adults above 19 years of age the proposed intake is approximately 100 times lower. This level of anticipated intake is considered a high intake scenario as opposed to a worst-case situation. The data provided suggest the absence of adverse effects of lactoferrin at the proposed levels of consumption. The Panel concludes that the novel food ingredient bLF is safe under the proposed uses and use levels. © European Food Safety Authority, 2012 KEY WORDSBovine lactoferrin, novel food, ingredient Bovine lactoferrin (bLF) is a protein that occurs naturally in cow"s milk. The applicant intends to market bLF in isolated and purified form. bLF is an iron-binding glycoprotein of approximately 77 kDa and consists of a single polypeptide chain of about 700 amino acids. The sequence homology between human and bLF is about 70 %. The tertiary structure of this glycoprotein has two ironbinding sites, giving it the capability to bind two Fe 3+ ions per molecule of protein. Batch testing confirmed that the product complies with the given specifications. bLF from skimmed milk is concentrated via ion exchange and is subsequently subjected to filtration steps. Ultimately the bLF is dried by means of spray drying. The applicant provided sufficient information regarding the specification, manufacture, composition and stability of bLF.The applicant intends to market bLF as an ingredient for food supplements, infant and follow-on formulae, dietetic food for special medical purposes and sports nutrition, and for foods such as nonalcoholic beverages, cakes and pastries, products derived from cheese, milk-based products, cold snacks...

show abstract

Impact of Lactoferrin Supplementation on Growth and Prevalence ofGiardiaColonization in Children

Cited by 78 publications

References 11 publications

Antimicrobial Activity of Lactoferrin-Related Peptides and Applications in Human and Veterinary Medicine

Antimicrobial Activity of Lactoferrin-Related Peptides and Applications in Human and Veterinary Medicine

Effect of lactoferrin on enteric pathogens

Scientific Opinion on bovine lactoferrin

Contact Info

Product

Resources

About